Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

It works by mimicking a hormone called glucagon-like peptide-1, or GLP-1, which stimulates the body’s production of insulin.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

ABSTRACT: Obesity has become a global chronic metabolic disease, posing a serious threat to public health. Glucagon-like peptide-1 (GLP-1) is an important hormone secreted by the L cells of the small ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Department of Bioengineering, Imperial College London, South Kensington, London SW72AZ, United Kingdom Diabetes and Obesity Theme, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty ...

as well as an oral peptide delivery technology, according to Evercore ISI analysts. Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist). It is a peptide or, in other words, a very short protein. This is the active ingredient in Ozempic, Wegovy ...

Glucagon-like peptide 1 (GLP-1), for example, is a peptide secreted by the gastrointestinal tract in response to food intake, which leads to the secretion of insulin and inhibition of glucagon ...

I will be particularly interested in the company’s plan to attract and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

Relative effects of genetically proxied glucagon‐like peptide‐1 receptor agonism on muscle and fat mass: A Mendelian randomization study. Diabetes, Obesity and Metabolism , 2025; DOI: 10.1111 ...